Eli Lilly And Co (NYSE:LLY) Major Shareholder Lilly Endowment Inc Sells 10,598 Shares of Stock

Eli Lilly And Co (NYSE:LLY) major shareholder Lilly Endowment Inc sold 10,598 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $114.00, for a total transaction of $1,208,172.00. Following the sale, the insider now directly owns 116,210,304 shares of the company’s stock, valued at $13,247,974,656. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Monday, November 11th, Lilly Endowment Inc sold 100 shares of Eli Lilly And Co stock. The shares were sold at an average price of $114.07, for a total transaction of $11,407.00.
  • On Wednesday, November 6th, Lilly Endowment Inc sold 173,918 shares of Eli Lilly And Co stock. The shares were sold at an average price of $114.05, for a total transaction of $19,835,347.90.
  • On Monday, November 4th, Lilly Endowment Inc sold 7,003 shares of Eli Lilly And Co stock. The shares were sold at an average price of $114.04, for a total transaction of $798,622.12.
  • On Thursday, October 31st, Lilly Endowment Inc sold 190,000 shares of Eli Lilly And Co stock. The shares were sold at an average price of $114.00, for a total transaction of $21,660,000.00.
  • On Friday, September 20th, Lilly Endowment Inc sold 210,000 shares of Eli Lilly And Co stock. The shares were sold at an average price of $116.37, for a total transaction of $24,437,700.00.

LLY opened at $115.10 on Wednesday. The firm has a market cap of $108.68 billion, a P/E ratio of 20.74, a PEG ratio of 1.85 and a beta of 0.16. Eli Lilly And Co has a 1-year low of $101.36 and a 1-year high of $132.13. The company has a 50 day simple moving average of $110.55 and a two-hundred day simple moving average of $112.44. The company has a debt-to-equity ratio of 4.09, a current ratio of 1.17 and a quick ratio of 0.88.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 23rd. The company reported $1.48 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.43 by $0.05. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The business had revenue of $5.48 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same period in the prior year, the business posted $1.39 earnings per share. The company’s revenue was up 3.2% on a year-over-year basis. Equities analysts anticipate that Eli Lilly And Co will post 5.79 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $0.645 per share. The ex-dividend date of this dividend is Thursday, November 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.24%. Eli Lilly And Co’s dividend payout ratio is 46.49%.

LLY has been the subject of a number of recent analyst reports. Bank of America initiated coverage on shares of Eli Lilly And Co in a research report on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price target for the company. UBS Group dropped their price target on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research report on Thursday, October 17th. Finally, TheStreet upgraded shares of Eli Lilly And Co from a “c+” rating to a “b-” rating in a research report on Friday, November 8th. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $130.03.

Large investors have recently modified their holdings of the stock. Selective Wealth Management Inc. bought a new position in shares of Eli Lilly And Co during the third quarter worth $25,000. Enterprise Trust & Investment Co bought a new position in shares of Eli Lilly And Co during the third quarter worth $27,000. Garrett Wealth Advisory Group LLC bought a new position in shares of Eli Lilly And Co during the third quarter worth $29,000. Quest Capital Management Inc. ADV bought a new position in shares of Eli Lilly And Co during the third quarter worth $34,000. Finally, Prestige Wealth Management Group LLC bought a new position in shares of Eli Lilly And Co during the second quarter worth $34,000. Hedge funds and other institutional investors own 76.52% of the company’s stock.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: What is meant by holder of record?

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.